| 05.31.24 | Novartis spokescelebs confirm Cosentyx is ‘Still Working’; AbbVie celebrates psoriasis patients in gallery show - Questex (2024)

Text-only version of this email

Brand LogoPHARMA MARKETINGA message from Fierce Pharma Marketing Awardseeeeeeeeeee aaaaaaaaaaaaaaa En Jles ar CLENE ikTODAY’S BIG NEWSMay 31, 2024Novartis standbys Cyndi Lauper, Michelle Bernstein unite to report Cosentyx is ‘Still Working’----------------------------------------------------------------------------------------------------------------------------------New AbbVie photo exhibit captures psoriasis patients—including 'Scandal' star Katie Lowes—feeling 'Clearly Me'----------------------------------------------------------------------------------------------------------------------------------First Wave BioPharma comes ashore with new name as it prepares for phase 3 trial----------------------------------------------------------------------------------------------------------------------------------No treachery here: Celltrion signs ‘Traitor’ star Mollie Pearce for bowel disease campaignThe Top Line Podcast: don’t miss out on the newest episode where we discuss ASCO data, rising health tech stars, and more. Listennow.A message from EpocratesWEBINAR: TRUST TRANSFORMED: PHARMA MARKETING IN THE POST-COOKIE ERATuesday, June 11, 2024 | 2pm ET / 11am PTThis webinarconvenes top industry experts to discuss the transition to privacy-centric, cookie-less marketing solutions that notonly ensure compliance but also enhance user engagement.Register now.FEATUREDNOVARTIS STANDBYS CYNDI LAUPER, MICHELLE BERNSTEIN UNITE TO REPORT COSENTYX IS 'STILL WORKING'By Andrea ParkNearly a decade into Cosentyx’s tenure as an FDA-approved treatment for plaque psoriasis and psoriatic arthritis, Novartis hastapped two of its go-to celebrity spokespeople to confirm that the drug is still working for them.TOP STORIESNEW ABBVIE PHOTO EXHIBIT CAPTURES PSORIASIS PATIENTS—INCLUDING 'SCANDAL' STAR KATIE LOWES—FEELING 'CLEARLY ME'By Andrea ParkAbbVie’s newest psoriasis awareness-raising campaign is taking the skin condition out of the spotlight.FIRST WAVE BIOPHARMA COMES ASHORE WITH NEW NAME AS IT PREPARES FOR PHASE 3 TRIALBy Andrea ParkThe company formerly known as First Wave BioPharma has found itself on dry land with a decidedly non-aquatic new moniker.NO TREACHERY HERE: CELLTRION SIGNS 'THE TRAITORS' STAR MOLLIE PEARCE FOR BOWEL DISEASE CAMPAIGNBy Ben AdamsSouth Korean biosimilar company Celltrion is signing up Mollie Pearce, a contestant on the British TV show “The Traitors,” to helpfront its latest “Where’s Crohn’s & Colitis?” campaign.A message from medisafeWEBINAR: UNLOCKING THE MYSTER: DATA & INNOVATION IN WOMEN'S HEALTHTuesday, June 18, 2024 | 11am ET / 8am PTETJoin this webinar and discover how leading agencies are unlocking innovations in women's health. Learn how the NIH's novelopportunity map and Medisafe's data-driven insights are cracking the code on PCOS and other female-specific conditions. Hearfirsthand how patients are empowered to take control of their health through this data.VERONA'S ENSIFENTRINE WILL BE A 'PARADIGM SHIFT IN COPD TREATMENT,' GLOBALDATA SAYSBy Kevin DunleavyWith Verona Pharmaceuticals' COPD candidate ensifentrine approaching its FDA decision date, GlobalData has referred to it as a“paradigm shift in COPD treatment.” Additionally, ICER has estimated that ensifentrine would meet cost-effectiveness thresholds atan annual price between $7,500 and $12,700 per year.AMGEN GRABS FDA THUMBS-UP FOR SOLIRIS BIOSIM, EYES 2025 LAUNCHBy Eric SagonowskyAmgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its plannedStelarabiosim rollout in 2025. But thanks to a new FDA approval, the company is nearing yet another biosimilar launch.EVIDENCE DOESN'T SUPPORT FDA'S USE OF SURROGATE MARKERS FOR ACCELERATED APPROVALS: REPORTBy Kevin DunleavyA recent report from the Yale School of Medicine and Emory University shows that there is little evidence backing the FDA's use ofsurrogate markers to determine if a medicine is fit for an accelerated approval.BIOTECH FACES A RECKONING: 'WE'VE LOST OUR LUSTER IN CELL THERAPIES'By Annalee ArmstrongA Special Report from the Fierce Biotech team on the state of cell therapy.Fierce podcastsDON’T MISS AN EPISODETHE TOP LINEAUTOMATION, DECENTRALIZATION AND THE FUTURE OF CAR-TSThis week’s episode of “The Top Line,” is the final part ofa three-part series diving into the latest advancements in cell andgene therapy manufacturing.ADVANCEMENTS IN CELL & GENE THERAPY MANUFACTURING (PART II)A LOOK AT TELEHEALTH'S FUTURE AND AN OMNICHANNEL APPROACH TO CAREA message from Smart CommunicationsSURVEY: DIGITALLY TRANSFORMING DATA COLLECTION IN PHARMAWe need your help! Please share your thoughts and opinions on how data is collected within your organization, and plans fordigitally revolutionizing form-driven business processes. All qualified respondents that complete the survey will be entered towin a $250 Amazon gift. Take the survey now.RESOURCESeBookGET TO ESIGNATURE FASTER: MAXIMIZE THE VALUE OF YOUR ESIGNATURE INVESTMENT WITH TRUE FORMS AUTOMATIONThis eBook offers insights for business leaders looking to do more with reduced budgets by using the power of SmartIQ’s true formsautomation to eliminate the need to print, sign, and scan/mail physical documents, increase operational efficiency, and reducedisparate systems.Sponsored by: SmartComms LLCResearchTAPPING THE POWER OF CONSUMER ATTITUDESDownload this research report to discover how a new predictive model built on consumer attitudinal data can generate improvedresults for health marketers.Sponsored by: Quad MediaWhitepaperDRIVING DTC ADOPTION WITH TELEHEALTH PROGRAMSVirtual care programs represent a compelling opportunity for decision makers in life sciences companies to drive growth,innovation, and value creation. Download now to learn more.Sponsored by: WheelWhitepaperSPEED LITERATURE REVIEWS 3X WITH AIHow one top pharma increased literature reviews efficiency by 3x powered by AI -- download todaySponsored by: IQVIAWhitepaperUSING SYNTHESIS AND ROUTE DESIGN TECHNOLOGY TO APPROACH API COMPLEXITYSmall molecule active pharmaceutical ingredients (APIs) continue to grow more complex. Download the white paper to learn moreabout using synthesis and route design technology to approach API complexity.Sponsored by: LonzaINDUSTRY EVENTSDrug Development Boot Camp® VIRTUAL | Spring 2024April ‌10-11, ‌2024On HelixDate: ‌4 ‌July ‌2024 ‌- ‌Location: ‌Babraham ‌Research ‌Campus, ‌Cambridge ‌UKUPCOMING FIERCE EVENTS8-9JulPharma PR & Communications Summit EastJersey City, NJ9-12SepDigital Pharma EastPhiladelphia, PA11SepFierce Pharma Marketing Awards GalaPhiladelphia, PA17-19SepDigital Pharma East Virtual EventVirtual Event25-26SepMedical Affairs Strategic Summit WestSan Diego, CAView all eventsBrand LogoLinkedin LogoTwitter LogoConnectAdvertiseContactSubscriptionsContact SupportOur teamSenior Editor: Ben AdamsDeputy Editor: Andrea ParkEditor-in-Chief: Ayla EllisonPublisher: Rebecca WillumsonGroup Sales Director: Angelique AlcoverThis email was sent to [emailprotected] as part of the Fierce Pharma email list./\\f SRS RIS RO K/ %J&j& L\

The Latest Emails Sent By Questex

More Emails, Deals & Coupons From Questex

Email Offers, Discounts & Promos From Our Top Stores